Alpha-synuclein in the Cerebrospinal Fluid Differentiates Synucleinopathies (Parkinson Disease, Dementia With Lewy Bodies, Multiple System Atrophy) From Alzheimer Disease

McKhann, 1984, Clinical diagnosis of Alzheimers disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimers disease., Neurology, 34, 939, 10.1212/WNL.34.7.939

McKeith, 2004, Dementia with Lewy bodies., Lancet Neurol, 3, 19, 10.1016/S1474-4422(03)00619-7

Hughes, 1992, Accuracy of clinical diagnosis of idiopathic Parkinsons disease: a clinico-pathological study of 100 cases., J Neurol Neurosurg Psychiatry, 55, 181, 10.1136/jnnp.55.3.181

Gilman, 2008, Second consensus statement on the diagnosis of multiple system atrophy., Neurology, 71, 670, 10.1212/01.wnl.0000324625.00404.15

Mollenhauer, 2008, Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration., Exp Neurol, 213, 315, 10.1016/j.expneurol.2008.06.004

Hong, 2010, DJ-1 and a-synuclein in human cerebrospinal fluid as biomarkers of Parkinsons disease., Brain, 133, 713, 10.1093/brain/awq008

Tokuda, 2006, Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinsons disease., Biochem Biophys Res Commun, 349, 162, 10.1016/j.bbrc.2006.08.024

Kasuga, 2010, Differential levels of a-synuclein, b-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimers disease., J Neurol Neurosurg Psychiatry, 81, 608, 10.1136/jnnp.2009.197483

Borghi, 2000, Full length a-synuclein is present in cerebrospinal fluid from Parkinsons disease and normal subjects., Neurosci Lett, 287, 65, 10.1016/S0304-3940(00)01153-8

Spies, 2009, Cerebrospinal fluid alpha-synuclein does not discriminate between dementia disorders., J Alzheimers Dis, 16, 363, 10.3233/JAD-2009-0955

Noguchi-Shinohara, 2009, CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimers disease., Brain Res, 1251, 1, 10.1016/j.brainres.2008.11.055

Orimo, 2007, Degeneration of cardiac sympathetic nerve begins in the early disease process of Parkinsons disease., Brain Pathol, 17, 24, 10.1111/j.1750-3639.2006.00032.x

Kikuchi, 2010, In vivo visualization of a-synuclein deposition by carbon-11-labelled 2-2-(2-dimethylaminothiazol- 5-yl)ethenyl-6-2-(fluoro) ethoxy benzoxazole positron emission tomography in multiple system atrophy., Brain, 133, 1772, 10.1093/brain/awq091

Nemani, 2010, Increased expression of SNCA reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis., Neuron, 65, 66, 10.1016/j.neuron.2009.12.023

Paleologou, 2009, Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies., Brain, 132, 1093, 10.1093/brain/awn349

Westerlund, 2008, Cerebellar alpha-synuclein levels are decreased in Parkinsons disease and do not correlate with SNCA polymorphisms associated with disease in a Swedish material., FASEB J, 22, 3509, 10.1096/fj.08-110148

Meulener, 2005, DJ-1 is present in a large molecular complex in human brain tissue and interacts with alpha-synuclein., J Neurochem, 93, 1524, 10.1111/j.1471-4159.2005.03145.x

Jin, 2007, Identification of novel proteins affected by rotenone in mitochondria of dopaminergic cells., BMC Neurosci, 5, 845

Hansson, 2006, Association between CSF biomarkers and incipient Alzheimers disease in patients with mild cognitive impairment: a follow-up study., Lancet Neurol, 5, 228, 10.1016/S1474-4422(06)70355-6

Culvenor, 1999, Non-amyloid beta component of Alzheimers disease amyloid (NAC) revisited. NAC and alpha-synuclein are not associated with Abeta amyloid., Am J Pathol, 155, 1173, 10.1016/S0002-9440(10)65220-0

Crews, 2009, Role of synucleins in Alzheimers disease., Neurotox Res, 16, 306, 10.1007/s12640-009-9073-6

Devi, 2010, Mitochondrial trafficking of APP and alpha synuclein: relevance to mitochondrial dysfunction in Alzheimers and Parkinsons diseases., Biochim Biophys Acta, 1802, 11, 10.1016/j.bbadis.2009.07.007

Esposito, 2007, Alpha-synuclein and its disease-related mutants interact differentially with the microtubule protein tau and associate with the actin cytoskeleton., Neurobiol Dis, 26, 521, 10.1016/j.nbd.2007.01.014

Choi, 2006, Fine epitope mapping of monoclonal antibodies specific to human alpha-synuclein., Neurosci Lett, 397, 53, 10.1016/j.neulet.2005.11.058

Giasson, 2000, A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinsons disease., J Neurosci Res, 59, 528, 10.1002/(SICI)1097-4547(20000215)59:4<528::AID-JNR8>3.0.CO;2-0

Formichi, 2006, Cerebrospinal fluid tau, a beta, and phosphorylated tau protein for the diagnosis of Alzheimers disease., J Cell Physiol, 208, 39, 10.1002/jcp.20602

Frasier, 2005, Tau phosphorylation increases in symptomatic mice overexpressing A30P alpha-synuclein., Exp Neurol, 192, 274, 10.1016/j.expneurol.2004.07.016

Conway, 2000, Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to earlyonset Parkinsons disease: implications for pathogenesis and therapy., Proc Natl Acad Sci USA, 97, 571, 10.1073/pnas.97.2.571